<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pyridostigmine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00545</strong>&#160; (APRD00380)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A cholinesterase inhibitor with a slightly longer duration of action than neostigmine. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00545/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00545/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00545.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00545.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00545.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00545.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00545.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00545">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Bromure de Pyridostigmine</td><td>French</td><td>INN</td></tr><tr><td>Bromuro de piridostigmina</td><td>Spanish</td><td>INN</td></tr><tr><td>Pyridostigmin bromid</td><td>German</td><td>INN</td></tr><tr><td>Pyridostigmini Bromidum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Pyridostigmine Bromide</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000190/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000190/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: VNYBTNPBYXSMOO-UHFFFAOYSA-M</li>
              <li>Monoisotopic Mass: 260.016040317</li>
              <li>Average Mass: 261.116</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000190">DBSALT000190</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Amiasten</td><td>AC Farma</td></tr><tr><td>Amygra</td><td>Tabros</td></tr><tr><td>Antilon</td><td>Yuan Chou</td></tr><tr><td>Astinon</td><td>Samarth</td></tr><tr><td>Kalymin</td><td>Arzneimittelwerk Dresden</td></tr><tr><td>Kalymin forte</td><td>Temmler</td></tr><tr><td>Kalymin N</td><td>Temmler</td></tr><tr><td>Kalymin retard</td><td>Temmler</td></tr><tr><td>Meshanon60</td><td>Hasan</td></tr><tr><td>Mestinon</td><td>Valeant</td></tr><tr><td>Mestinon retard</td><td>Meda</td></tr><tr><td>Mestinon-SR</td><td>Valeant</td></tr><tr><td>Myestin</td><td>VHB</td></tr><tr><td>Pyridostigmine Bromide</td><td>CorePharma</td></tr><tr><td>Pyrimine</td><td>Sriprasit Dispensary</td></tr><tr><td>Regonol</td><td>Organon</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antimyasthenic-agents">Antimyasthenic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>155-97-5</td></tr><tr><th>Weight</th><td>Average: 181.2117<br>Monoisotopic: 181.09770267</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>RVOLLAQWKVFTGE-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C)C(=O)OC1=C[N+](C)=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyridines and Derivatives</td></tr><tr><th>Subclass</th><td>Pyridinium Derivatives</td></tr><tr><th>Direct parent</th><td>Pyridinium Derivatives</td></tr><tr><th>Alternative parents</th><td>Tertiary Amines; Carbamic Acids and Derivatives; Ethers; Polyamines</td></tr><tr><th>Substituents</th><td>carbamic acid derivative; tertiary amine; ether; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyridinium derivatives. These are compounds containing a pyridinium ring, which is the cationic form of pyridine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of myasthenia gravis.</td></tr><tr><th>Pharmacodynamics</th><td>Pyridostigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Since it is a quaternary amine, it is poorly absorbed in the gut and doesn't cross the blood-brain barrier. Pyridostigmine has a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.</td></tr><tr><th>Mechanism of action</th><td>Pyridostigmine inhibits acetylcholinesterase in the synaptic cleft by competing with acetylcholine for attachment to acetylcholinesterase, thus slowing down the hydrolysis of acetylcholine, and thereby increases efficiency of cholinergic transmission in the neuromuscular junction and prolonges the effects of acetylcholine.</td></tr><tr><th>Absorption</th><td>Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hydrolysis by cholinesterases and by liver.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3 hours following oral administration.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9441</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9818</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6465</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.737</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.915</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8654</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8863</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7541</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7082</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.586</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9341</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9274</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9782</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8422</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9193
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.5528
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1468 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9248
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8484
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Valeant pharmaceuticals international</li>
<li>Sandoz canada inc</li>
<li>Barr laboratories inc</li>
<li>Corepharma llc</li>
<li>Impax laboratories inc</li>
<li>Solvay pharmaceuticals</li>
<li>United states army office surgeon general</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Barr Pharmaceuticals</li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li><a href="http://www.dsm.com">DSM Corp.</a></li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Oceanside Pharmaceuticals Incorporated</li>
<li>Professional Co.</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li>Southcoast Pharmaceuticals Inc.</li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB01285">Corticotropin</a></td><td>The corticosteroid, corticotropin, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB01380">Cortisone acetate</a></td><td>The corticosteroid, cortisone acetate, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The corticosteroid, methylprednisolone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB01384">Paramethasone</a></td><td>The corticosteroid, paramethasone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, pyridostigmine.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to decrease adverse effects.</li></ul></td></tr></tbody></table>